Lixisenatide (Adlyxin)
Overview
A selective GLP-1 receptor agonist derived from exendin-4 with a modified C-terminal tail containing six lysine residues. Lixisenatide has a half-life of approximately 3 hours and primarily reduces postprandial glucose through potent delay of gastric emptying rather than fasting glucose reduction. It is designed for once-daily use as an add-on to basal insulin therapy in type 2 diabetes.
Key Research Findings
FDA-approved in 2016 for type 2 diabetes. GetGoal clinical trial program demonstrated effective postprandial glucose control. ELIXA cardiovascular outcomes trial confirmed cardiovascular safety. Available as a fixed-ratio combination with insulin glargine (Soliqua 100/33).
Subcutaneous injection (daily)
FDA Approved
Interested in Lixisenatide (Adlyxin)?
Find a verified provider experienced with Lixisenatide (Adlyxin) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Lixisenatide (Adlyxin) ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.